Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Amy Perez

Nurse Practitioner Seattle, WA Nurse Practitioner

NPI 1366075780 CMS profile 10653993

1100 9Th Ave, Seattle, WA 98101

Open in the dashboard

General payments

$13,594

256 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amy Perez of Seattle, WA is reported in the CMS Open Payments database as having received $13,594 across 256 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,005 64
2024 General $2,259 86
2023 General $2,525 34
2022 General $2,603 44
2021 General $1,202 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Perez
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Amy Perez were reported at $5,005. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Amy Perez Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,202 $135 $40–$426 $132
2022 $2,603 $152 $48–$470 $149
2023 $2,525 $166 $54–$529 $160
2024 $2,259 $173 $55–$556 $164
2025 $5,005 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Edwards Lifesciences Corporation $4,922 61 payments
  2. Abbott Laboratories $2,593 61 payments
  3. Boston Scientific Corporation $2,533 40 payments
  4. Medtronic, Inc. $1,027 15 payments
  5. Abiomed $520 17 payments
  6. Shockwave Medical, Inc $401 8 payments
  7. Novartis Pharmaceuticals Corporation $228 17 payments
  8. CHF Solutions, Inc $216 2 payments
  9. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $215 16 payments
  10. E.R. Squibb & Sons, L.L.C. $211 2 payments
  11. Other $728 17 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,697 236 payments
  2. Travel and Lodging $3,787 16 payments
  3. Gift $75 1 payment
  4. Education $35 3 payments
Products named General payments · program years 2021–2025
  1. SAPIEN 3 Ultra RESILIA $1,828 27 payments
  2. NAVITOR $1,321 11 payments
  3. WATCHMAN Access System $1,208 9 payments
  4. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $785 9 payments
  5. MITRACLIP $503 5 payments
  6. Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter $367 7 payments
  7. Impella $330 8 payments
  8. WATCHMAN FLX $305 20 payments
  9. SYMPLICITY G3 $295 2 payments
  10. WATCHMAN $274 3 payments
  11. Other $3,704 128 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

54

Median for Nurse Practitioner: 389

Drug cost

$7,038

Median for Nurse Practitioner: $21,885

Branded share of claims

79.6%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Brilinta Ticagrelor Brand 17 $6,651
Clopidogrel Clopidogrel Bisulfate Brand 26 $301
Pantoprazole Sodium Generic 11 $85

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 14 billing codes

Paid by Medicare

$1,969

Medicare's payments for the services billed

Medicare patients

40

Average age 80

Services billed

53

21 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Heart failure 75%
Ischemic heart disease 75%
Atrial fibrillation 58%
Chronic kidney disease 50%
Arthritis 45%
Diabetes 30%
COPD 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

256 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record